title: [A descriptive analysis of naratriptan use among migraineurs in ambulatory medicine].
abstract: The objective of this study was to provide an epidemiological description of naratriptan use in ambulatory medicine. 1695 patients were recruited by 384 primary care physicians and 111 neurologists, and followed for 12 weeks. Physicians had to document the migraine history, and to report symptoms and health care in a structured case report form. Patients were to document each episode of migraine (EM) in a diary. At baseline, 45 p.cent of the patients reported their migraine treatment as unsatisfactory. Ninety-eight percent of included patients were migraineurs according to criteria of the International Headache Society (IHS), including migrainous disorders. Ninety-two percent of naratriptan prescriptions were established in the second intention in patients with migraine, according to the IHS classification, including migrainous disorders. A total of 79 p.cent of patients had complied with the good practices for all EMs. More appropriate health education strategies should target the small group of patients who over-use naratriptan, and patients with aura. However, this study shows that naratriptan tends to be correctly prescribed by physicians, and used by patients with acute migraine.
authors.forename: F
authors.initials: F
authors.lastname: Brudon-Mollard
authors.forename: P-L
authors.initials: PL
authors.lastname: Druais
authors.forename: A
authors.initials: A
authors.lastname: Giacomino
authors.forename: P
authors.initials: P
authors.lastname: Hinault
authors.forename: M
authors.initials: M
authors.lastname: Lanteri-Minet
authors.forename: M
authors.initials: M
authors.lastname: Zaïm
authors.forename: J
authors.initials: J
authors.lastname: Chemali-Hudry
authors.forename: A
authors.initials: A
authors.lastname: El Hasnaoui
mesh_terms: D000208:Acute Disease; D000328:Adult; D000553:Ambulatory Care / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology; D010880:Piperidines / Q000627:therapeutic use*; D011446:Prospective Studies; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D007211:Indoles; D010880:Piperidines; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C106783:naratriptan